scholarly journals Long‐term treatment with the oncolytic ECHO‐7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient‐three case reports

Apmis ◽  
2016 ◽  
Vol 124 (10) ◽  
pp. 896-904 ◽  
Author(s):  
Pēteris Alberts ◽  
Evija Olmane ◽  
Linda Brokāne ◽  
Zanda Krastiņa ◽  
Māra Romanovska ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Reports ◽  
Stage Iv ◽  
Term Treatment ◽  
Small Cell ◽  
Cancer Stage ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Long Term Treatment

scholarly journals Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed

2019 ◽  
Vol Volume 12 ◽  
pp. 5355-5358
Author(s):  
Masayuki Takeda ◽  
Kazuko Sakai ◽  
Kazuto Nishio ◽  
Kazuhiko Nakagawa
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Term Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Treatment

Efficacy of platinum rechallenge chemotherapy in sensitive relapsed small cell lung cancer after a long-term treatment-free interval.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e18554-e18554
Author(s):  
Yasushi Murakami ◽  
Hideo Saka ◽  
Masahide Oki ◽  
Chiyoe Kitagawa ◽  
Yoshihito Kogure
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Term Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Free Interval ◽  
Long Term Treatment

scholarly journals Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +)

2018 ◽  
pp. 68-72
Author(s):  
A. M. Lozhkina ◽  
M. A. Sviridenko ◽  
A. O. Cheremnykh ◽  
E. A. Filippova ◽  
M. A. Urtenova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Case ◽  
Term Treatment ◽  
Small Cell ◽  
Chemotherapy Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Long Term Treatment ◽  
Alk Positive

The article describes a clinical case of ALK-positive non-small cell lung cancer and its long-term treatment with a chemotherapy drug pemetrexed as first-line regimen followed by pemetrexed maintenance therapy.

Non-Small Cell Lung Cancer Stage IV Long-Term Survival With Isolated Spleen Metastasis

2013 ◽  
Vol 95 (4) ◽  
pp. 1432-1434 ◽  
Author(s):  
Rodrigo A.S. Sardenberg ◽  
Clovis Pinto ◽  
Cynthia A. Bueno ◽  
Riad N. Younes
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Stage Iv ◽  
Small Cell ◽  
Cancer Stage ◽  
Small Cell Lung ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Pneumonectomy with carinal resection in patients with non-small cell lung cancer: short and long-term results

2018 ◽  
Vol 20 (4) ◽  
pp. 36-40
Author(s):  
I A Dadyev ◽  
M M Davydov ◽  
A G Abdullaev ◽  
I O Kulik ◽  
Z A Ambalova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Treatment Outcomes ◽  
Term Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Resection Group ◽  
Carinal Resection ◽  
Long Term Treatment ◽  
Short And Long Term

Objective. With to compare short- and long-term treatment outcomes of different carinal resection techniques in patients with non-small cell lung cancer (NSCLC) and carina involvement. Materials and methods. We performed retrospective nonrandomized clinical trial with following groups of patients: patients underwent pneumonectomy with sleeve carinal resection (47 patients); patients underwent pneumonectomy with marginal and wedge carinal resection (18 patients). Statistical analysis was made using Statistic 6.0 program. Case-control analysis of the both groups was performed to evaluate short- and long-term treatment outcomes of different carinal resection techniques in patients with NSCLC and carina involvement. Results. Frequency of non-surgical and surgical complications was 27.7% and 18.5% correspondingly. Postoperative mortality was 8.5% in sleeve carinal resection group and 11.1% in marginal and wedge carinal resection group. Five-year survival rates were 32.6% in sleeve carinal resection group and 11.1% in marginal wedge carinal resection group.

scholarly journals Negativation of PD-L1 Postoperatively in Initially Inoperable Stage III Non-Small Cell Lung Cancer Treated with Pembrolizumab: Two Case Reports

2019 ◽  
Vol 12 (2) ◽  
pp. 421-425
Author(s):  
Fadi Nasr ◽  
Ahmad Al Ghoche ◽  
Roland Eid ◽  
Lewis Nasr ◽  
Saada Diab ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Incidental Finding ◽  
Case Reports ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Iiia Nsclc

Stage III non-small cell lung cancer is a border line stage between localized and metastatic disease. PDL-1 is gaining an important role in the therapeutic arsenal of lung cancer, the most frequent cancer worldwide. We report for the first time a negativation of PDL-1 status in 2 cases of stage IIIA NSCLC with conversion to operable disease after using immunotherapy. The first patient was a 59-year old female diagnosed incidentally to have stage IIIA inoperable NSCLC that was treated with combination chemo-immunotherapy, and converted to operable disease with a negative PD-L1 in the postoperative setting. The second case is that of a 56-year old male that also had an inoperable stage IIIA NSCLC treated with chemotherapy first line followed by pembrolizumab at progression, then operated after surgical conversion, with negative PD-L1 postoperatively. In front of these findings, further work should be done to elucidate if the reverse of the PDL-1 status and the conversion to operability were due to the use of immunotherapy or to an incidental finding. If confirmed, it may have a therapeutic impact.

Sign in / Sign up

Export Citation Format

Share Document